Avoid grapefruit
Avoid grapefruit and grapefruit juice.
Leaflet RUXOLITINIB MSN 20mg tablets
- Product code:
- W71883001
- Quantity:
- 56
- Indicated for:
- cancer
- Route of administration:
- oral
- Substance:
- ruxolitinib (JAK inhibitor)
- ATC
- L01EJ01 — Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Janus-associated kinase (JAK) inhibitors
Precautions:
Avoid live vaccines
Avoid live vaccines during treatment if contraindicated.
Immunosuppression / infection risk
This medicine may increase the risk of infections.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Ruxolitinib is a selective inhibitor of Janus kinases (JAK1 and JAK2) used in the treatment of myelofibrosis, polycythemia vera, and atopic dermatitis. It works by inhibiting the JAK-STAT signaling pathways, reducing inflammation and abnormal cell proliferation associated with these conditions.
Ruxolitinib is administered orally, usually twice daily, and is indicated for patients with intermediate or high-risk myelofibrosis, as well as those with polycythemia vera who are resistant to hydroxyurea. It is commonly used to reduce splenomegaly, alleviate symptoms, and improve patients' quality of life.
Common side effects include anemia, thrombocytopenia, infections, and dizziness. In rare cases, severe adverse reactions such as opportunistic infections or bone marrow failure may occur. Regular monitoring of hematologic parameters is essential for dose adjustment and prevention of complications.
Ruxolitinib represents an innovative therapeutic option for patients with myeloproliferative disorders, offering significant benefits in managing symptoms and disease progression.
Ruxolitinib is administered orally, usually twice daily, and is indicated for patients with intermediate or high-risk myelofibrosis, as well as those with polycythemia vera who are resistant to hydroxyurea. It is commonly used to reduce splenomegaly, alleviate symptoms, and improve patients' quality of life.
Common side effects include anemia, thrombocytopenia, infections, and dizziness. In rare cases, severe adverse reactions such as opportunistic infections or bone marrow failure may occur. Regular monitoring of hematologic parameters is essential for dose adjustment and prevention of complications.
Ruxolitinib represents an innovative therapeutic option for patients with myeloproliferative disorders, offering significant benefits in managing symptoms and disease progression.
General data about RUXOLITINIB MSN 20mg
- Substance:
- ruxolitinib
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W71883001
- Concentration:
- 20mg
- Pharmaceutical form:
- tablets
- Quantity:
- 56
- Product type:
- Generic medicine
- Prescription status:
- P-6L — Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.
Pharmaceutical forms available for ruxolitinib
Concentrations available for ruxolitinib
- 10mg
- 15mg
- 15mg/g
- 20mg
- 5mg
- 5mg/ml